Vancouver-based psychedelic drugs company Clearmind Medicine has entered a license agreement with BIRAD, an R&D company of Bar-Ilan University, to use their joint patent for a pioneering treatment for cocaine addiction.
The partnership stems from Clearmind's successful preclinical trials using its novel psychedelic molecule, 5-Methoxy-2-aminoindane (MEAI), to treat cocaine addiction. The clinical study suggested MEAI could eliminate heightened cocaine cravings and showed it was not addictive.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.